If you’re still waiting for a low-cost, affordable version of prescription cholesterol drugs Vytorin or Zetia, you may have to wait a while longer. Teva Pharmaceuticals has settled a lawsuit with Merck & Co. over the cholesterol drugs, and agreed not to sell generic versions of Vytorin and Zetia until April 2017. Considering Vytorin and Zetia each run about $125 a month, it’s no surprise that cholesterol patients who were looking for more affordable alternatives are disappointed in the news.
But all is not lost! Generic drug giant Mylan Inc. is still fighting Merck & Co. for the right to sell their generic versions of Vytorin and Zetia in the U.S. Merck & Co. is trying to block the sale of Mylan’s generic Vytorin and Zetia in a trial scheduled to start on December 5th, and you can be sure that we’ll be following it!
- Savings Tip: Have You Asked Your Doctor for a Vytorin Multi-Use Savings Card?
- Generic Drug Alert: Patent on Strattera Ruled Invalid, Generic Versions Of Strattera to Hit the Market
- Blood Pressure Drugs Cozaar and Hyzaar to Finally Go Generic
- Generic Drug Questions: When Will Generic Singulair Be Available in the U.S.?
- Will A Legal Fight Over Generic Lipitor Bring Prices Down?